As the race to develop and distribute a potential Covid-19 vaccine accelerates around the world, Russian coronavirus vaccine candidate Sputnik V, also touted as the world’s first registered Covid-19 vaccine, will have a price ‘much lower’ than other covid vaccines like the Pfizer and Modern candidates, according to the developers at Sputnik V.
“Translating pharmaceutical jargon: Pfizer’s advertised price of $ 19.50 and Moderna of $ 25 to $ 37 per dose actually means their price of $ 39 and $ 50 to $ 74 per person. Two doses per person are required to the Pfizer, Sputnik V and Modern Vaccines. The price of Sputnik V will be much lower, “tweeted the official Sputnik V account.
Sputnik V samples have already been sent to India, Hungary, Armenia, Belarus, and other countries for ongoing trials. Russian President Vladimir Putin said last week that dozens of other countries have also expressed a desire to buy Russian COVID vaccines, including EpiVacCorona, which was registered in October.
On August 11, the Sputnik V vaccine was registered by the Russian Ministry of Health and became the world’s first registered vaccine against COVID-19 based on the human adenoviral vector platform.
Earlier this month, developers at Sputnik V, RDIF and Gamaleya Institute, announced interim data from a large test that suggests the injection appears to be 92% effective.
The statement, which did not include detailed information about the trial, comes just two days after a similar one from Pfizer Inc., but is based on far fewer virus cases. Some experts suggest that the data may have been released quickly in an effort to keep up with the global race for a successful coronavirus vaccine.
On November 17, Moderna, in its official statement, had announced that the independent Data Security Monitoring Board (DSMB), designated by the US NIH for the Phase 3 study of mRNA-1273, informed Modern that the trial met the previous statistical criteria specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.
The US-based pharmaceutical giant will charge governments between $ 25 and $ 37 per dose of its COVID-19 vaccine candidate, depending on the amount requested, CEO Stephane Bancel told German weekly Welt am Sonntag ( WamS).
Similarly, on November 18, Pfizer-BioNTech developed the final results of the candidate vaccine from the last stage of the trial of its coronavirus vaccine that was found to be 95% effective and had no serious side effects in older people. .
With contributions from the agency
.
